Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Total Thyroidectomy With and Without Neck Dissections
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Drain output
研究概览
简要总结
This is a single-blinded randomized controlled trial to evaluate the effectiveness of Arista hemostatic matrix powder (Arista® AH, C. R. Bard, Inc. Davol, Warwick, RI) in reducing drainage output after total thyroidectomy with and without lateral neck dissections. Increased drainage in total thyroidectomy and neck dissection wound beds can lead to seroma formation with possible secondary infection, delayed hospital discharge, and additional home care needs for drain care. Arista is an inert plant based absorbable surgical hemostatic powder that can be easily applied to broad surgical fields to reduce bleeding and seroma rates. Therefore, its application to thyroidectomy and neck dissection wound beds may bear significant potential benefit.
详细描述
This is a single-blinded randomized controlled trial to evaluate the effectiveness of Arista hemostatic matrix powder in reducing drainage output after total thyroidectomy with and without lateral neck dissections. Increased drainage in total thyroidectomy and neck dissection wound beds can lead to seroma formation with possible secondary infection, delayed hospital discharge, and additional home care needs for drain care. Arista is an inert plant based absorbable surgical hemostatic powder that can be easily applied to broad surgical fields to reduce bleeding and seroma rates. Therefore, its application to thyroidectomy and neck dissection wound beds may bear significant potential benefit.
Specific Aim 1: The main hypothesis of the study is that the use of Arista in total thyroidectomy with and without lateral neck dissections prior to closure will reduce postoperative drain outputs and time to drain removal compared to total thyroidectomy with and without lateral neck dissection closed without Arista.
Specific Aim 2: This study will also evaluate the secondary hypotheses that Arista will reduce postoperative hematoma and seroma rates and hospital length of stay in total thyroidectomies with and without lateral neck dissections.
INTRODUCTION
Total thyroidectomy is an increasingly common procedure performed where the entire thyroid gland is removed for either benign or malignant disease. Common indications include multinodular goiter, Graves disease, and thyroid carcinoma. Between 2006 and 2011 the number of total thyroidectomies performed in the United States increased by 12% per year, from 45,558 to 72,344 according the to the American Cancer Society. In 2011 48,000 total thyroidectomies were performed for malignant disease which often requires additional lateral neck dissection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients undergoing Total Thyroidectomy with or without lateral neck dissection
- •Patient must be 18 years of age or older.
- •The patient must have capacity to be able to sign a study-specific informed consent prior to study
排除标准
- •Pregnancy (for female patients).
- •Patients who will require anticoagulant medications other than routine DVT prophylaxis within 8 days postoperatively.
- •Presence of clotting or bleeding disorder.
研究组 & 干预措施
3
Thyroidectomy with neck + Arista
干预措施: Arista (Device)
4
Thyroidectomy with neck
2
Thyroidectomy
1
thyroidectomy + Arista
干预措施: Arista (Device)
结局指标
主要结局
Drain output
时间窗: 1-14 days after Surgery
Measured output from closed suction drain in ml. This will be recorded every 12 hrs until drain is removed.
次要结局
- Seroma (Rate of clinically relevant seroma complications)(1-14 days after surgery)
